ChloRaCo Healthcare Limited
ChloRaCo Healthcare Limited
Registered number: 09957949
Financial Statements
For the Period 1 August 2023 to 31 March 2024
Corinthian Tax LLP
ChloRaCo Healthcare Limited
Contents
Contents
| Page | |
|---|---|
| Balance Sheet | 1—2 |
| Notes to the Financial Statements | 3—6 |
ChloRaCo Healthcare Limited
Balance Sheet
As At
31 March 2024
Balance Sheet
Registered number:
09957949
For the period ending 31 March 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.
The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime.
The company has taken advantage of section 444(1) of the Companies Act 2006 and opted not to deliver to the registrar a copy of the company's Profit and Loss Account.
| 31 March 2024 | 31 July 2023 | ||||
|---|---|---|---|---|---|
| Notes | £ | £ | £ | £ | |
| FIXED ASSETS | |||||
| Intangible Assets | 4 |
|
|
||
| Tangible Assets | 5 |
|
|
||
|
|
|
||||
| CURRENT ASSETS | |||||
| Stocks | 6 |
|
|
||
| Debtors | 7 |
|
|
||
|
|
|
||||
| Creditors: Amounts Falling Due Within One Year | 8 |
( |
( |
||
| NET CURRENT ASSETS (LIABILITIES) |
( |
( |
|||
| TOTAL ASSETS LESS CURRENT LIABILITIES |
( |
( |
|||
| Creditors: Amounts Falling Due After More Than One Year | 9 |
( |
( |
||
| NET LIABILITIES |
( |
( |
|||
| CAPITAL AND RESERVES | |||||
| Called up share capital |
|
|
|||
| Profit and Loss Account |
( |
( |
|||
| SHAREHOLDERS' FUNDS | (144,198) | (166,187) | |||
ChloRaCo Healthcare Limited
Balance Sheet (continued)
As At
31 March 2024
On behalf of the board
|
Director
|
|
|
The notes on pages 3 to 6 form part of these financial statements.
ChloRaCo Healthcare Limited
Notes to the Financial Statements
For the Period 1 August 2023 to 31 March 2024
Notes to the Financial Statements
1.
General Information
ChloRaCo Healthcare Limited
is a private company, limited by shares, incorporated in England & Wales, registered number
09957949
. The registered office is Sykeside View, Burnley Road, Altham, Accrington, BB5 5UH.
2.
Accounting Policies
2.1.
Basis of Preparation of Financial Statements
The financial statements have been prepared under the historical cost convention and in accordance with Financial Reporting Standard 102 section 1A Small Entities "The Financial Reporting Standard applicable in the UK and Republic of Ireland" and the Companies Act 2006.
2.2.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, net of discounts and value added taxes. Turnover includes revenue earned from the sale of goods and from the rendering of services. Turnover is reduced for estimated customer returns, rebates and other similar allowances.
Sale of goods
Turnover from the sale of goods is recognised when the significant risks and rewards of ownership of the goods has transferred to the buyer. This is usually at the point that the customer has signed for the delivery of the goods.
Rendering of services
Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs. Turnover is only recognised to the extent of recoverable expenses when the outcome of a contract cannot be estimated reliably.
2.3.
Intangible Fixed Assets and Amortisation - Other Intangible
Amortisation is charged to the profit and loss account over its estimated economic life of 4 years.
2.4.
Tangible Fixed Assets and Depreciation
Tangible fixed assets are measured at cost less accumulated depreciation and any accumulated impairment losses. Depreciation is provided at rates calculated to write off the cost of the fixed assets, less their estimated residual value, over their expected useful lives on the following bases:
| Freehold |
|
| Motor Vehicles |
|
| Fixtures & Fittings |
|
| Computer Equipment |
|
2.5.
Stocks and Work in Progress
Stocks and work in progress are valued at the lower of cost and net realisable value after making due allowance for obsolete and slow-moving stocks. Cost includes all direct costs and an appropriate proportion of fixed and variable overheads. Work-in-progress is reflected in the accounts on a contract by contract basis by recording turnover and related costs as contract activity progresses.
2.6.
Foreign Currencies
Monetary assets and liabilities in foreign currencies are translated into sterling at the rates of exchange ruling at the balance sheet date. Transactions in foreign currencies are translated into sterling at the rate ruling on the date of the transaction. Exchange differences are taken into account in arriving at the operating profit.
ChloRaCo Healthcare Limited
Notes to the Financial Statements (continued)
For the Period 1 August 2023 to 31 March 2024
2.7.
Taxation
Income tax expense represents the sum of the tax currently payable and deferred tax.
The tax currently payable is based on taxable profit for the year. Taxable profit differs from profit as reported in the statement of comprehensive income because of items of income or expense that are taxable or deductible in other year and items that are never taxable or deductible. The company's liability for current tax is calculated using tax rates that have been enacted or substantively enacted by the end of the reporting period.
Deferred tax is recognised on timing differences between the carrying amounts of assets and liabilities in the financial statements and the corresponding tax bases used in the computation of taxable profit. Deferred tax liabilities are generally recognised for all taxable timing differences. Deferred tax assets are generally recognised for all deductible temporary differences to the extent that it is probable that taxable profits will be available against which those deductible timing differences can be utilised. The carrying amount of deferred tax assets is reviewed at the end of each reporting period and reduced to the extent that it is no longer probable that sufficient taxable profits will be available to allow all or part of the asset to be recovered.
Deferred tax assets and liabilities are measured at the tax rates that are expected to apply in the period in which the liability is settled or the asset realised, based on tax rates (and tax laws) that have been enacted or substantively enacted by the end of the reporting period. Deferred tax liabilities are presented within provisions for liabilities and deferred tax assets within debtors. The measurement of deferred tax liabilities and asset reflects the tax consequences that would follow from the manner in which the Company expects, at the end of the reporting period, to recover or settle the carrying amount of its assets and liabilities.
Current or deferred tax for the year is recognised in profit or loss, except when they related to items that are recognised in other comprehensive income or directly in equity, in which case, the current and deferred tax is also recognised in other comprehensive income or directly in equity respectively.
3.
Average Number of Employees
Average number of employees, including directors, during the period was: 8 (2023: 9)
4.
Intangible Assets
| Other | |||
|---|---|---|---|
| £ | |||
| Cost | |||
| As at 1 August 2023 |
|
||
| As at 31 March 2024 |
|
||
| Amortisation | |||
| As at 1 August 2023 |
|
||
| Provided during the period |
|
||
| As at 31 March 2024 |
|
||
| Net Book Value | |||
| As at 31 March 2024 |
|
||
| As at 1 August 2023 |
|
||
5.
Tangible Assets
| Land & Property | ||||
|---|---|---|---|---|
| Freehold | Motor Vehicles | Fixtures & Fittings | Total | |
| £ | £ | £ | £ | |
| Cost | ||||
| As at 1 August 2023 |
|
|
|
|
| Additions |
|
|
|
|
| As at 31 March 2024 |
|
|
|
|
...CONTINUED
ChloRaCo Healthcare Limited
Notes to the Financial Statements (continued)
For the Period 1 August 2023 to 31 March 2024
| Depreciation | ||||
| As at 1 August 2023 |
|
|
|
|
| Provided during the period |
|
|
|
|
| As at 31 March 2024 |
|
|
|
|
| Net Book Value | ||||
| As at 31 March 2024 |
|
|
|
|
| As at 1 August 2023 |
|
|
|
|
6.
Stocks
| 31 March 2024 | 31 July 2023 | ||
|---|---|---|---|
| £ | £ | ||
| Stock |
|
|
|
7.
Debtors
| 31 March 2024 | 31 July 2023 | ||
|---|---|---|---|
| £ | £ | ||
| Due within one year | |||
| Trade debtors |
|
|
|
| Prepayments and accrued income |
|
|
|
| VAT |
|
|
|
| Directors' loan accounts |
|
|
|
|
|
|
||
| Due after more than one year | |||
| Other debtors |
|
|
|
| Deferred tax current asset |
|
|
|
|
|
|
||
|
|
|
||
8.
Creditors: Amounts Falling Due Within One Year
| 31 March 2024 | 31 July 2023 | ||
|---|---|---|---|
| £ | £ | ||
| Trade creditors |
|
|
|
| Bank loans and overdrafts |
|
|
|
| Other taxes and social security |
|
|
|
| Other creditors |
|
|
|
| Accruals and deferred income |
|
|
|
| Directors' loan accounts |
|
- | |
|
|
|
||
9.
Creditors: Amounts Falling Due After More Than One Year
| 31 March 2024 | 31 July 2023 | ||
|---|---|---|---|
| £ | £ | ||
| Other creditors > 1 year |
|
|
|
ChloRaCo Healthcare Limited
Notes to the Financial Statements (continued)
For the Period 1 August 2023 to 31 March 2024
10.
Directors Advances, Credits and Guarantees
Included within Debtors/Creditors are the following loans to/from the directors:
| As at 1 August 2023 | Amounts advanced | Amounts repaid | Amounts written off | As at 31 March 2024 | |
|---|---|---|---|---|---|
| £ | £ | £ | £ | £ | |
| Mrs Rachel Cookson |
|
|
|
- |
|
| Mr Gareth Jenkins |
|
|
|
- |
( |
The above loans are unsecured and repayable on demand.
11.
Additional note to the accounts
The sales performance continues to improve as the investment in new markets starts to be realised in terms of improved profitability. The outlook for the 2nd half of 2024 is very positive based on the execution of pharmaceutical tenders that have been won but were delayed due to external factors.
Further details regarding the trading position are available on request.